IBD: Infliximab dose optimization in IBD - Proactive or reactive?

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 12, 2014, Pages 706-708

  Armuzzi, Alessandro ^a   Felice, Carla ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

CONTROL STRATEGY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG EFFICACY; DRUG MONITORING; HUMAN; INFLAMMATORY BOWEL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REMISSION; RISK BENEFIT ANALYSIS; SHORT SURVEY; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; ULCERATIVE COLITIS; CLINICAL TRIAL (TOPIC); INFLAMMATORY BOWEL DISEASES; PROCEDURES; PROGNOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 84927176288     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.180     Document Type: Short Survey

References (9)

1. Vaughn, B. P. et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm. Bowel Dis. http://dx.doi.org/10.1097/MIB.0000000000000156.
2. Afif, W. et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105, 1133-1139 (2010).
3. Velayos, F. S., Kahn, J. G., Sandborn, W. J. & Feagan, B. G. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin. Gastroenterol. Hepatol. 11, 654-666 (2013).
4. Steenholdt, C. et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63, 919-927 (2014).
5. Adedokun, O. J. et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2014.08.035.
6. Cornillie, F. et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut http://dx.doi.org/10.1136/gutjnl-2012-304094.
7. Maser, E. A., Villela, R., Silverberg, M. S. & Greenberg, G. R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 1248-1254 (2006).
8. Levesque, B. G. et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment. Pharmacol. Ther. 39, 1126-1135 (2014).
9. Vande Casteele, N. et al. OP001. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the Taxit study. United European Gastroenterology Journal 1 (Suppl. 1), A1 (2013).